We investigated whether adipose-derived adult stromal (ADAS) are of neural crest origin and the extent to which Notch 1 regulates their growth and differentiation. Mouse ADAS cells cultured in media formulated for neural stem cells (NSC) displayed limited capacity for self-renewal, clonogenicity, and neurosphere formation compared to NSC from the subventricular zone in the hippocampus. Although ADAS cells expressed Nestin, GFAP, NSE and Tuj1 in vitro, exposure to NSC differentiation supplements did not induce mature neuronal marker expression. In contrast, in mesenchymal stem cell (MSC) media, ADAS cells retained their ability to proliferate and differentiate beyond 20 passages and expressed high levels of Nestin. In neuritizing cocktails, ADAS cells extended processes, downregulated Nestin expression, and displayed depolarization-induced Ca(2+) transients but no spontaneous or evoked neural network activity on Multi-Electrode Arrays. Deletion of Notch 1 in ADAS cell cultures grown in NSC proliferation medium did not significantly alter their proliferative potential in vitro or the differentiation-induced downregulation of Nestin. Co-culture of ADAS cells with fibroblasts that stably expressed the Notch ligand Jagged 1 or overexpression of the Notch intracellular domain (NICD) did not alter ADAS cell growth, morphology, or cellular marker expression. ADAS cells did not display robust expression of neural crest transcription factors or genes (Sox, CRABP2, and TH); and lineage tracing analyses using Wnt1-Cre;Rosa26R-lacZ or -EYFP reporter mice confirmed that fewer than 2% of the ADAS cell population derived from a Wnt1-positive population during development. In summary, although media formulations optimized for MSCs or NSCs enable expansion of mouse ADAS cells in vitro, we find no evidence that these cells are of neural crest origin, that they can undergo robust terminal differentiation into functionally mature neurons, and that Notch 1 is likely to be a key regulator of their cellular and molecular characteristics.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2180194PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001453PLOS

Publication Analysis

Top Keywords

adas cells
32
neural crest
16
adas
12
adas cell
12
cells
10
adipose-derived adult
8
adult stromal
8
stromal adas
8
crest origin
8
mouse adas
8

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Vaccinex, Inc., Rochester, NY, USA.

Background: The earliest recognized biomarker of AD is deposition of Aβ amyloid that leads to formation of plaques and may, over time, trigger or at least be followed by gliosis/neuroinflammation and neurofibrillary tangles, accompanied by neurodegenerative changes including neuronal and synaptic loss. We have previously reported that semaphorin 4D (SEMA4D), the major ligand of plexin B receptors expressed on astrocytes, is upregulated in diseased neurons during progression of AD and Huntington's disease (HD). Binding of SEMA4D to PLXNB receptors triggers astrocyte reactivity, leading to loss of neuroprotective homeostatic functions, including downregulation of glutamate and glucose transporters (doi:10.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Qingdao Municipal hospital, Qingdao university, Qingdao, Shandong, China.

Background: Complement C1q, the initiator of the classical pathway of the complement system, is activated during Alzheimer's disease (AD) development and progression and is especially associated with the β-amyloid and tau pathology. However, whether C1q influences AD pathology by modulating glial cell communication is unclear.

Method: Alzheimer's Disease Neuroimaging Initiative (ADNI, N = 217) was used to explore the association between cerebrospinal fuid (CSF) C1q, soluble triggering receptor expressed on myeloid cells 2 (sTREM2), Glial fbrillary acidic protein (GFAP), and AD biomarkers.

View Article and Find Full Text PDF

Background: Subcortical ischemic vascular cognitive impairment (SIVCI) is the most common form of vascular cognitive impairment. Exercise is a potentially effective intervention for SIVCI. However, the mechanisms through which exercise promotes brain health and cognitive function are not well understood.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Annovis Bio, Malvern, PA, USA.

Background: By inhibiting the translation of neurotoxic aggregating proteins - amyloid precursor protein, tau, alpha-synuclein etc., buntanetap restores axonal transport, lowers inflammation, and protects nerve cells from dying. Our Phase2 studies showed that buntanetap improved early AD patients ADAS-Cog11 after a month treatment.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Biomed Industries, Inc., San Jose, CA, USA.

Background: NA-831 is a candidate for the treatment of Alzheimer's Disease (AD). NA-911 is an analog of NA-831, serving as an IGF-1 and GLP-1 agonists. Animal studies of NA-911 are evaluated for the treatment of by hypoxic-ischemic injury, hemorrhagic stroke, and chronic neurodegenerative disorders METHOD: For NA-831: A randomized clinical trial of NA-831 was performed in 112 participants with mild and moderate AD, half received the drugs and half received placebo.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!